Iovance Biotherapeutics, Inc. (IOVA) Earnings History
Annual and quarterly earnings data from 2008 to 2025
Loading earnings history...
IOVA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IOVA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.2% | -153.1% | -148.4% |
| 2024 | 24.4% | -240.9% | -226.8% |
| 2023 | -804.5% | -38735.0% | -37345.4% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export IOVA earnings history in CSV or JSON format
Free sign-in required to download data
Iovance Biotherapeutics, Inc. (IOVA) Earnings Overview
As of May 8, 2026, Iovance Biotherapeutics, Inc. (IOVA) reported trailing twelve-month net income of -$354M, reflecting +14.8% year-over-year growth. The company earned $-0.85 per diluted share over the past four quarters, with a net profit margin of -148.4%.
Looking at the long-term picture, IOVA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$15,772 in fiscal 2009.
Iovance Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ADCT (-$137M net income, -175.3% margin), FATE (-$136M net income, -2051.1% margin), CRSP (-$569M net income, -16569.8% margin), IOVA has outperformed on profitability metrics. Compare IOVA vs ADCT →
IOVA Earnings vs Peers
Earnings metrics vs comparable public companies
IOVA Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$391M | -5.1% | -$403M | $-1.09 | -148.4% | -153.1% |
| 2024 | -$372M | +16.2% | -$395M | $-1.28 | -226.8% | -240.9% |
| 2023 | -$444M | -12.2% | -$461M | $-1.89 | -37345.4% | -38735.0% |
| 2022 | -$396M | -15.7% | -$399M | $-2.49 | - | - |
| 2021 | -$342M | -31.8% | -$343M | $-2.23 | - | - |
| 2020 | -$260M | -31.4% | -$262M | $-1.88 | - | - |
| 2019 | -$198M | -59.9% | -$207M | $-1.50 | - | - |
| 2018 | -$124M | -34.2% | -$128M | $-1.27 | - | - |
| 2017 | -$92M | -74.1% | -$93M | $-1.41 | - | - |
| 2016 | -$53M | -91.2% | -$54M | $-0.96 | - | - |
See IOVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IOVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IOVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIOVA — Frequently Asked Questions
Quick answers to the most common questions about buying IOVA stock.
Is IOVA growing earnings?
IOVA EPS stands at $-0.85, with +14.8% growth matching the 5-year CAGR of N/A. TTM net income is $-354M. Earnings trajectory remains consistent.
What are IOVA's profit margins?
Iovance Biotherapeutics, Inc. net margin is -148.4%, with operating margin at -153.1%. Below-average margins reflect competitive or cost pressures.
How consistent are IOVA's earnings?
IOVA earnings data spans 2008-2025. The current earnings trend is +14.8% YoY. Historical data enables comparison across business cycles.